Product Information
FLUTICASONE-SALMETEROL 232-14 is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $105.3214 per EA under NDC 00093360982. Its NADAC has been published 463 times since Nov 22, 2017.
FDA first approved this application on Jan 27, 2017.
Strength
232; 14 ug/1; ug/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093360982
Classification
Generic
Dosage Form
POWDER, METERED
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA208799FDA Approved
1/27/2017
On Market Since
4/28/2017
Pharmacological Classes
Price Statistics
The NADAC for FLUTICASONE-SALMETEROL 232-14 has been published 463 times since Nov 22, 2017, and over the history we have for it it has risen 24.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $105.3214 per EA |
|---|---|
| All-time high | $111.2732 (Apr 10, 2024) |
| All-time low | $82.2483 (Dec 22, 2021) |
| 52-week high | $111.0279 |
| 52-week low | $102.7556 |
| Median price | $93.7626 |
| Average price | $95.7459 |
| Largest weekly change | +17.8% (Apr 20, 2022) |
| Weeks tracked | 463 |
| Tracking since | Nov 22, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fluticasone Propionate and Salmeterol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FLUTICASONE-SALMETEROL 232-14?
The current National Average Drug Acquisition Cost (NADAC) for FLUTICASONE-SALMETEROL 232-14, manufactured by Teva Pharmaceuticals USA Inc., is $105.3214 per EA (NDC 00093360982), effective Sep 30, 2026.
How has the price of FLUTICASONE-SALMETEROL 232-14 changed over time?
Over the history we have for it, the NADAC for FLUTICASONE-SALMETEROL 232-14 has risen 24.2%. It has been tracked across 463 weekly CMS publications since Nov 22, 2017.
What are the highest and lowest recorded NADAC prices for FLUTICASONE-SALMETEROL 232-14?
Since Nov 22, 2017, the NADAC for FLUTICASONE-SALMETEROL 232-14 has ranged from a low of $82.2483 (Dec 22, 2021) to a high of $111.2732 (Apr 10, 2024), with a median of $93.7626 per EA.
Are there cheaper alternatives to FLUTICASONE-SALMETEROL 232-14?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as FLUTICASONE-SALMETEROL 232-14 in a comparable dosage form, but none are currently priced below it.
Who manufactures FLUTICASONE-SALMETEROL 232-14?
FLUTICASONE-SALMETEROL 232-14 (NDC 00093360982) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.